Compare Bristol-Myers Squibb Co (BMY) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Prudential Financial Inc — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while Prudential Financial Inc trades at $114.44 (market cap $39.87B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.9× Prudential Financial Inc's market cap, and Prudential Financial Inc pays the higher dividend (4.88%). Which is the better fit depends on your goals.
| BMY | PRU | |
|---|---|---|
Market Cap | $116.30B | $39.87B |
Sector | Health | Financials |
52-Week High | $62.37 | $118.72 |
52-Week Low | $42.60 | $92.00 |
Enterprise Value | $152.24B | $66.92B |
Dividend Yield | 4.42% | 4.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
PRU trades at $116.17, up 0.69% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 11.96, net income margin of 5.5%, and recent earnings beats in Q3 2025 and Q1 2026. Recent news highlights dividend payments and expansion into India's life insurance market.
The outlook is mixed; solid profitability and low valuation support upside, but analyst consensus is cautious with a $102.50 price target below current levels. Key risks include volatile cash flows and high debt levels. Earnings on August 4, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
